Pentamidine Intravenous for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Staff must wear gloves, goggles, mask and gown and must use a Closed System Transfer Device (CSTD)(e.g. Equashield or PhaSeal) to prepare this drug. This is to prevent exposure of health-care staff to the drug.
Equashield instructions
Equashield components required:
- a: VA20 vial adaptor (VA-20/2) - one for the water for injection 100ml bottle, and one for each vial of drug required
- b: 10ml Syringe unit (SU-10/2) - to draw up Water for injection to reconstitute drug (one syringe will do all vials required) and to draw up reconstituted solution
- c: spike adaptor (SA-IT) (to add reconstituted solution into the infusion bag)
Phaseal: see this video
Patients must be lying down for IV therapy due to the risk of hypotension- see 'Monitoring'
See under 'Dose' for adjustments required in renal impairment
Monitoring requirements - see overleaf
There are numerous important interactions- check BNF for details
Unlicensed preparation

Pentacarinat 300mg vial

For intravenous infusion

Reconstitute using Water for Injections from a 100mL vial (available in pharmacy).
- the 100ml vial should be used as the plasco ampoules are not suitable as they cannot connect to Equashield.
Using a Closed System Transfer Device (CSTD)- see Important information: add 3 to 5ml Water for Injection to 300mg vial
Dilute further prior to administration

For nebulisation

In most situations, this is prepared by Pharmacy Aseptics Services Unit (PASU)
In the event that it cannot be prepared by PASU, prepare as follows:
- Reconstitute using Water for Injections from a 100mL vial (available in pharmacy).
  - the 100ml vial should be used as the plasco ampoules are not suitable as they cannot connect to Equashield.
- Using a Closed System Transfer Device (CSTD)- see Important information: add 4 to 6ml Water for Injection to 300mg vial

Glucose 5% or Sodium chloride 0.9%

Intermittent intravenous infusion (using an electronically controlled infusion device)

Using a Closed System Transfer Device (CSTD)- see Important information: add required dose to 100 to 250ml infusion fluid
Administer over at least 60 minutes (usually 60 to 120 minutes)

Pneumocystis jirovecii pneumonia (PJP) treatment

Give 4mg per kg once daily for 14 to 21 days (Non HIV) to 21 days (HIV) ^{(ref 2)}
May prolong QT interval. Use with caution in at risk patients
Patients must be lying down for IV therapy due to the risk of hypotension during and following administration - see 'Monitoring'

Trypanosomiasis (ref BNF)

Can be given by deep IM injection or by intravenous infusion
Give 4mg per kg once daily, or on alternate days to complete a total of seven or ten doses

Visceral and Cutaneous Leishmaniasis

Renal impairment (PJP indication)^{(ref 2)}

Indication	eGFR (ml/min/1.73m²)	Dose
All indications	10 to 50ml	Use usual dose ^{(ref 2)}
Severe infection	less than 10ml	4mg per kg daily for seven to ten days then	4mg per kg on alternate days to complete a minimum of 14 doses (but see Further information)
Non-severe infection	less than 10ml	4mg per kg on alternate days to complete a minimum of 14 doses (but see further information below)
Nephrotoxic effects may be additive therefore avoid other nephrotoxic drugs.

Careful monitoring required - severe reactions, sometimes fatal, due to hypotension, hypoglycaemia, acute pancreatitis and cardiac arrhythmias have occurred
Monitor blood pressure closely before starting treatment, during administration and several times thereafter, until treatment has concluded
Daily U+E
Daily blood glucose measurements during therapy and continuing several times after completion of therapy as required by patient's clinical condition. Hyperglycaemia and diabetes mellitis, with or without preceding hypoglycaemia have occurred up to several months after cessation of therapy
Daily FBC and platelet count
LFTs weekly, or every 3 to 5 days if values are elevated
Calcium levels - weekly
Magnesium levels - twice weekly
ECG at regular intervals (QT interval prolongation can occur)

Phlebitis can occur after intravenous or intramuscular administration
Extravasation may cause tissue damage. If extravasation occurs, the infusion should be discontinued immediately, and restarted in another vein
Pentamidine is used by nebulisation for prophylaxis of PJP at a dose of 300mg every month. It has also been used by nebulisation for treatment of PJP - consult specialist literature.
Staff preparing this drug must wear gloves, goggles, mask and gown - and a Closed System Transfer Device (CSTD)
Renal impairment- all reference sources checked suggest that the treatment course is 14 doses - which equates to 28 days

SPC Pentacarinat 13th August 2019

1:Injectable medicines guide Medusa, downloaded 20/02/2023

Drug for pneumocystis pneumonia